Mathematical Modeling Identifies LAG3 and HAVCR2 As Biomarkers of T cell Exhaustion in Melanoma

Overview

Journal iScience

Publisher Cell Press

Date 2023 May 14

PMID 37182110

Authors

Richard J Beck

Sander Sloot

Hirokazu Matsushita

Kazuhiro Kakimi

Joost B Beltman

Affiliations

Soon will be listed here.

Abstract

Cytotoxic T lymphocytes (CTLs) control tumors via lysis of antigen-presenting targets or through secretion of cytokines such as interferon-γ (IFNG), which inhibit tumor cell proliferation. Improved understanding of CTL interactions within solid tumors will aid the development of immunotherapeutic strategies against cancer. In this study, we take a systems biology approach to compare the importance of cytolytic versus IFNG-mediated cytostatic effects in a murine melanoma model (B16F10) and to dissect the contribution of immune checkpoints HAVCR2, LAG3, and PDCD1/CD274 to CTL exhaustion. We integrated multimodal data to inform an ordinary differential equation (ODE) model of CTL activities inside the tumor. Our model predicted that CTL cytotoxicity played only a minor role in tumor control relative to the cytostatic effects of IFNG. Furthermore, our analysis revealed that within B16F10 melanomas HAVCR2 and LAG3 better characterize the development of a dysfunctional CTL phenotype than does the PDCD1/CD274 axis.

References

Zaidi M . The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res. 2018; 39(1):30-38. PMC: 6350411. DOI: 10.1089/jir.2018.0087. View

Gibney G, Weiner L, Atkins M . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542-e551. PMC: 5702534. DOI: 10.1016/S1470-2045(16)30406-5. View

Hoekstra M, Bornes L, Dijkgraaf F, Philips D, Pardieck I, Toebes M . Long-distance modulation of bystander tumor cells by CD8 T cell-secreted IFNγ. Nat Cancer. 2020; 1(3):291-301. PMC: 7305033. DOI: 10.1038/s43018-020-0036-4. View

Cazaux M, Grandjean C, Lemaitre F, Garcia Z, Beck R, Milo I . Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J Exp Med. 2019; 216(5):1038-1049. PMC: 6504219. DOI: 10.1084/jem.20182375. View

Harvat B, Seth P, Jetten A . The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene. 1997; 14(17):2111-22. DOI: 10.1038/sj.onc.1201055. View

Berg S, Kutra D, Kroeger T, Straehle C, Kausler B, Haubold C . ilastik: interactive machine learning for (bio)image analysis. Nat Methods. 2019; 16(12):1226-1232. DOI: 10.1038/s41592-019-0582-9. View

De Boer R, Homann D, Perelson A . Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol. 2003; 171(8):3928-35. DOI: 10.4049/jimmunol.171.8.3928. View

Steinert E, Schenkel J, Fraser K, Beura L, Manlove L, Igyarto B . Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. Cell. 2015; 161(4):737-49. PMC: 4426972. DOI: 10.1016/j.cell.2015.03.031. View

Liu Y, Bewersdorf J, Stahl M, Zeidan A . Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?. Blood Rev. 2018; 34:67-83. DOI: 10.1016/j.blre.2018.12.001. View

10.

Hegde U, Mukherji B . Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunol Immunother. 2017; 66(9):1113-1121. PMC: 5579167. DOI: 10.1007/s00262-017-2007-x. View

11.

Sharpe A, Pauken K . The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2017; 18(3):153-167. DOI: 10.1038/nri.2017.108. View

12.

Tang J, Pearce L, ODonnell-Tormey J, Hubbard-Lucey V . Trends in the global immuno-oncology landscape. Nat Rev Drug Discov. 2018; 17(11):783-784. DOI: 10.1038/nrd.2018.167. View

13.

Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M . Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol Res. 2014; 3(1):26-36. DOI: 10.1158/2326-6066.CIR-14-0098. View

14.

Hu Z, Ye L, Xing Y, Hu J, Xi T . Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice. Sci Rep. 2018; 8(1):217. PMC: 5760644. DOI: 10.1038/s41598-017-18641-y. View

15.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

16.

Guo Y, Xiao P, Lei S, Deng F, Xiao G, Liu Y . How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai). 2008; 40(5):426-36. DOI: 10.1111/j.1745-7270.2008.00418.x. View

17.

Beck R, Weigelin B, Beltman J . Mathematical Modelling Based on In Vivo Imaging Suggests CD137-Stimulated Cytotoxic T Lymphocytes Exert Superior Tumour Control Due to an Enhanced Antimitotic Effect on Tumour Cells. Cancers (Basel). 2021; 13(11). PMC: 8197176. DOI: 10.3390/cancers13112567. View

18.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

19.

Qomlaqi M, Bahrami F, Ajami M, Hajati J . An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. Math Biosci. 2017; 292:1-9. DOI: 10.1016/j.mbs.2017.07.006. View

20.

Mempel T, Henrickson S, von Andrian U . T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004; 427(6970):154-9. DOI: 10.1038/nature02238. View